China Medical System stock falls 1.97 percent and CMS adds iron drugs

Published on 10/08/2026 at 08:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

China Medical System stock gains a new 15-year China drug agreement dated October 6, 2026. Quarterly revenue reached CNY 4,500.73 million, up from CNY 4,210.08 million.

CMS, KYG211081248, Illustration mit AI erstellt.

China Medical System (KYG211081248) stock was trading at HKD 10.44 on October 8, 2026, at 2:40 p.m. HKT, down 1.97 percent from HKD 10.65. On October 6, 2026, the company secured exclusive China commercialization rights for Monofer and Cosmofer under a 15-year agreement with Pharmacosmos A/S, as Vehement Finance News Network reported.

Fifteen years of iron rights

The agreement gives CMS exclusive rights to commercialize the two intravenous iron products in mainland China, excluding Hong Kong, Macau and Taiwan. Both therapies are already approved in China and included in the National Reimbursement Drug List, while Cosmofer also holds Category A status and appears on the National Essential Medicines List, according to Vehement Finance News Network.

Monofer supports high-dose iron replacement in a single visit, while Cosmofer adds a second established option for iron deficiency and iron-deficiency anemia. The commercial logic is concentrated in CMS's existing specialty networks, particularly cardiology, nephrology, gastroenterology and related hospital channels.

Quarterly revenue moves higher

CMS reported quarterly revenue of CNY 4,500.73 million and net income of CNY 986.10 million in its latest release dated August 17, 2026. Revenue increased from CNY 4,210.08 million in the previous quarter, while net income rose from CNY 547.71 million, according to Investing.com.

That sequential revenue increase was 6.91 percent, while the reported net income comparison was 80.05 percent. The figures give the iron portfolio a financial backdrop, although the agreement itself does not disclose a revenue contribution or earnings forecast.

Analysts see higher valuation

Investing.com lists a Strong Buy consensus from 10 analysts and an average 12-month price target of HKD 17.67. The target lies 69.3 percent above the HKD 10.44 trading price on October 8, 2026.

The market capitalization stood at HKD 25.4 billion on October 8, 2026, with 1,879,000 shares traded at the quoted time. The 52-week range of HKD 9.51 to HKD 15.52 places the current price 32.73 percent below the yearly high and 9.78 percent above the yearly low.

CMS stock stays below yearly high

China Medical System stock was last at HKD 10.44 on the Hong Kong S.E. on October 8, 2026, at 2:40 p.m. HKT. The next valuation checkpoint is whether new products can convert the company's specialty distribution network into measurable sales growth.